Lenalidomide Mercury Pharmaceuticals Ltd.

Lenalidomide, the active ingredient in Lenalidomide Mercury Pharmaceuticals Ltd., is an immunomodulatory drug (IMiD) presented as a tablet for oral use. It treats multiple myeloma, myelodysplastic syndromes with del(5q), and mantle cell lymphoma in adult patients.

GNH USA supplies Lenalidomide Mercury Pharmaceuticals Ltd. as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Lenalidomide is used in hematologic malignancies and related disorders, targeting abnormal plasma cells and dysplastic bone‑marrow clones. - Multiple myeloma: improves response rates and prolongs progression‑free survival. - Myelodysplastic syndromes with del(5q): reduces transfusion dependence and improves peripheral blood counts. - Mantle cell lymphoma: induces remission in relapsed or refractory disease.

Lenalidomide may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Neutropenia: reduced white blood cell count. - Thrombocytopenia: lowered platelet levels. - Fatigue: persistent tiredness. - Nausea: upset stomach and vomiting.

Serious or Rare Side Effects: - Venous thromboembolism: blood clots in veins. - Severe neutropenia or thrombocytopenia: risk of infection or bleeding. - Secondary primary malignancies: emergence of new cancers. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Before initiating therapy, clinicians should assess patient risk factors and monitor for complications. - Monitor blood counts: perform regular CBCs to detect cytopenias. - Assess thrombotic risk: consider prophylactic anticoagulation for high‑risk patients. - Avoid pregnancy: teratogenic; enforce effective contraception. - Adjust dose in renal impairment: follow prescribing guidelines for reduced clearance. - Store at ambient temperature: keep below 25°C, protect from moisture and light.

Lenalidomide can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin): markedly reduce lenalidomide exposure. - Anticoagulants (e.g., warfarin): increase bleeding risk. - Live vaccines: heightened infection risk due to immunomodulation. - Immunosuppressants: may diminish therapeutic efficacy.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole): raise plasma concentrations. - NSAIDs: elevate risk of thrombocytopenia. - CYP2C19 inhibitors: potential impact on metabolism. - P‑gp inhibitors: may increase systemic exposure.